-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the improvement of the pharmaceutical innovation environment, the promotion of centralized procurement and other policies, the influx of talents, the domestic pharmaceutical industry has accelerated the transformation and upgrading, and the R&D focus of pharmaceutical companies has shifted from generic drugs to innovative drugs
.
Judging from the drugs approved in China in recent years, although most drugs are me-too drugs, some are first-in-class drugs
.
The industry pointed out that most me-too drugs are developed by start-ups that are transformed from generic drugs, because such drugs are less risky and may develop faster, but there is less innovation, and the development process of first-in-class drugs is long.
, And the investment is large, the risk is high, and the failure rate is very high with the great uncertainty
.
It is worth mentioning that although the risks of first in class are relatively large, the returns are relatively high.
With the rise of domestic innovative drugs, the field of First-in-Class innovative drugs has also attracted many investors
.
In the past month, two pharmaceutical companies completed financing to accelerate the development of First-in-Class innovative drugs
.
On September 26 news, Inno Pharmaceuticals recently announced the completion of tens of millions of US dollars in Series B financing.
This round of financing was led by the Shanghai Biomedical Fund, with Shanlan Capital, Tiliang Investment, Huasai Zhikang and Shangshi Tianxin.
Old shareholder Zhang Ke led the additional investment
.
It is reported that the company is carrying out a phase I clinical trial of a highly selective small molecule drug for a key inflammation pathway in Australia and has completed the China IND application at the same time
.
In this round of financing, the company will have part of the funds used to support subsequent clinical trials of the project
.
According to the data, Yinuo Pharmaceutical focuses on the research and development of a class of new drugs.
Through a deep understanding of complex disease mechanisms and key nodes of the signal network, guided by bioinformatics, it is committed to the development of First-in-Class drugs
.
The company integrates informatics into all aspects of research and development, and develops differentiated research strategies starting from solving clinical needs and pain points
.
At present, the company has built a product pipeline with autoimmune diseases and metabolic complications as the core and taking into account the combination drug strategy, and has formed a "gradient advancement" product development strategy to ensure that at least one project enters the clinical application stage every year
.
In addition, other pipeline projects of the company are also proceeding in an orderly manner
.
On September 13th, Yinming Biotechnology announced that it has recently completed nearly 50 million US dollars in A+ round of financing
.
Because Ming Bio's original investors Gaorong Capital, Jingcheng Capital, and Huacheng Venture Capital continue to invest in additional investment, new investors Franciscan Capital, Yixian E-commerce, Haisong Capital, Yifeng Capital, Taixin Capital, etc.
have joined this round of financing
.
According to the data, Yinming Bio has more than ten kinds of products under research in the fields of ophthalmic drugs, new medical and aesthetic drugs, small molecule immune drugs and cell therapy, most of which are competitive breakthrough First-in-Class innovative drugs.
, And the main products have completed the preliminary research and development or have achieved commercialization
.
Among them, the First-in-Class new ophthalmic drug for dry AMD passed the US IND in May this year and officially launched a phase I clinical trial
.
According to reports, since 2021, Yinming Bio has entered a stage of rapid development.
Blockbuster drug candidates such as dry AMD, new botulinum toxins, and new small molecule immunologic drugs have entered or will enter clinical trials in China and the United States as planned
.
This round of financing will accelerate the clinical trials of these blockbuster pipeline drug candidates
.
It is worth mentioning that in the past six months, Yinming has completed two consecutive rounds of financing, with a cumulative financing amount of nearly 110 million U.
S.
dollars
.
.
Judging from the drugs approved in China in recent years, although most drugs are me-too drugs, some are first-in-class drugs
.
The industry pointed out that most me-too drugs are developed by start-ups that are transformed from generic drugs, because such drugs are less risky and may develop faster, but there is less innovation, and the development process of first-in-class drugs is long.
, And the investment is large, the risk is high, and the failure rate is very high with the great uncertainty
.
It is worth mentioning that although the risks of first in class are relatively large, the returns are relatively high.
With the rise of domestic innovative drugs, the field of First-in-Class innovative drugs has also attracted many investors
.
In the past month, two pharmaceutical companies completed financing to accelerate the development of First-in-Class innovative drugs
.
On September 26 news, Inno Pharmaceuticals recently announced the completion of tens of millions of US dollars in Series B financing.
This round of financing was led by the Shanghai Biomedical Fund, with Shanlan Capital, Tiliang Investment, Huasai Zhikang and Shangshi Tianxin.
Old shareholder Zhang Ke led the additional investment
.
It is reported that the company is carrying out a phase I clinical trial of a highly selective small molecule drug for a key inflammation pathway in Australia and has completed the China IND application at the same time
.
In this round of financing, the company will have part of the funds used to support subsequent clinical trials of the project
.
According to the data, Yinuo Pharmaceutical focuses on the research and development of a class of new drugs.
Through a deep understanding of complex disease mechanisms and key nodes of the signal network, guided by bioinformatics, it is committed to the development of First-in-Class drugs
.
The company integrates informatics into all aspects of research and development, and develops differentiated research strategies starting from solving clinical needs and pain points
.
At present, the company has built a product pipeline with autoimmune diseases and metabolic complications as the core and taking into account the combination drug strategy, and has formed a "gradient advancement" product development strategy to ensure that at least one project enters the clinical application stage every year
.
In addition, other pipeline projects of the company are also proceeding in an orderly manner
.
On September 13th, Yinming Biotechnology announced that it has recently completed nearly 50 million US dollars in A+ round of financing
.
Because Ming Bio's original investors Gaorong Capital, Jingcheng Capital, and Huacheng Venture Capital continue to invest in additional investment, new investors Franciscan Capital, Yixian E-commerce, Haisong Capital, Yifeng Capital, Taixin Capital, etc.
have joined this round of financing
.
According to the data, Yinming Bio has more than ten kinds of products under research in the fields of ophthalmic drugs, new medical and aesthetic drugs, small molecule immune drugs and cell therapy, most of which are competitive breakthrough First-in-Class innovative drugs.
, And the main products have completed the preliminary research and development or have achieved commercialization
.
Among them, the First-in-Class new ophthalmic drug for dry AMD passed the US IND in May this year and officially launched a phase I clinical trial
.
According to reports, since 2021, Yinming Bio has entered a stage of rapid development.
Blockbuster drug candidates such as dry AMD, new botulinum toxins, and new small molecule immunologic drugs have entered or will enter clinical trials in China and the United States as planned
.
This round of financing will accelerate the clinical trials of these blockbuster pipeline drug candidates
.
It is worth mentioning that in the past six months, Yinming has completed two consecutive rounds of financing, with a cumulative financing amount of nearly 110 million U.
S.
dollars
.
